Euroapi

Euroapi LT Debt/Equity

The Long-Term Debt to Equity Ratio of Euroapi (EAPI.PA) as of Oct 31, 2026 is 0.02. In the previous year, Long-Term Debt to Equity Ratio was 0.01 — a change of 54.12% (higher).

LT Debt/Equity

0.02

YoY

54.12%

Last updated:

Long-Term Debt to Equity Ratio of Euroapi is 2025 0.02 . Long-Term Debt to Equity Ratio of Euroapi was 2024 0.01 . It decreases by 54.12% higher compared to the previous year.

The Euroapi LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
0.02 EUR
Jan 1, 2020
0.02 EUR
Jan 1, 2021
0.02 EUR
Jan 1, 2022
0.01 EUR
Jan 1, 2023
0.02 EUR
Jan 1, 2024
0.01 EUR
Jan 1, 2025
0.02 EUR
The Euroapi LT Debt/Equity history
YEARLT Debt/EquityYoY
0.02+54.12%
0.01-19.67%
0.02+14.50%
0.01-21.07%
0.02+18.78%
0.02-10.97%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Long-Term Debt to Equity Ratio of Euroapi is 0.02 in 2025.

Long-Term Debt to Equity Ratio of Euroapi changed from 0.01 to 0.02, representing a 54.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Euroapi since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Euroapi with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Euroapi

All Key Metrics — Euroapi